SP777SHOULD WE ASSESS COMBINATION OF CYP3A5 AND MDR-1 GENE POLYMORPHISMS TO OPTIMISE TACROLIMUS DOSE IN RENAL TRANSPLANT RECIPIENT. (13th June 2019)